Explore the intriguing findings from the post hoc analysis of the SONAR trial, shedding light on the potential analgesic effects of atrasentan. Uncover how this groundbreaking research could revolutionize pain management in tropical medicine, and the implications it holds for future studies.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Post hoc analysis of the SONAR trial: potential analgesic effects of atrasentan?
Iwagami, Kidney Int 2023
DOI: 10.1016/j.kint.2023.09.018
Chan et al. performed a post hoc analysis of the Study of Diabetic Nephropathy with Atrasentan (SONAR). They found that atrasentan reduced chronic pain-related adverse events and the need for analgesics. However, the study has limitations:
- The pain data was collected as part of adverse events, not as a primary focus.
- The baseline pain status of the participants was not known.
This study contributes to the literature by suggesting a potential new use for atrasentan in pain management. However, prospective clinical trials are needed to validate these findings. This is important as it could lead to improved pain management strategies for patients with diabetic nephropathy.